STOCK TITAN
  1. Home
  2. Sec-filings
  3. QNRX
  4. [Form 4] Quoin Pharmaceuticals, Ltd. Insider Trading Activity

[Form 4] Quoin Pharmaceuticals, Ltd. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Quoin Pharmaceuticals (QNRX) director Dennis Langer reported a purchase of 15,152 ADS on 10/14/2025 at a combined price of $8.49 per ADS in a private placement. Each ADS was purchased together with one Series H, Series I, Series J, and Series K warrant to buy one ADS.

The filing lists warrants for 15,152 ADS each with exercise prices of $9.075 (Series H), $10.3125 (Series I), and $12.375 (Series J and K). The warrants were exercisable immediately, subject to a beneficial ownership cap, and include milestone-based expirations tied to FDA-related events or a Priority Review Voucher sale, or five years from the closing date, whichever occurs earlier as specified for each series.

Following the reported transactions, Langer beneficially owned 15,153 ADS directly. Each ADS represents 35 ordinary shares of the company.

Positive

  • None.

Negative

  • None.
Insider LANGER DENNIS
Role Director
Bought 75,760 shs ($129K)
Type Security Shares Price Value
Purchase Series H Warrants (Right to Buy) 15,152 $0.00 $0.00
Purchase Series I Warrants (Right to Buy) 15,152 $0.00 $0.00
Purchase Series J Warrants (Right to Buy) 15,152 $0.00 $0.00
Purchase Series K Warrants (Right to Buy) 15,152 $0.00 $0.00
Purchase ADSs 15,152 $8.49 $129K
Holdings After Transaction: Series H Warrants (Right to Buy) — 15,152 shares (Direct); Series I Warrants (Right to Buy) — 15,152 shares (Direct); Series J Warrants (Right to Buy) — 15,152 shares (Direct); Series K Warrants (Right to Buy) — 15,152 shares (Direct); ADSs — 15,153 shares (Direct)
Footnotes (7)
  1. F1. Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
  2. F2. Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."
  3. F3. The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
  4. F4. The Series H Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the Company's public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome.
  5. F5. The Series I Warrants will expire as follows: (i) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome, and (ii) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome.
  6. F6. The Series J Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome.
  7. F7. The Series K Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the Company's sale of a Priority Review Voucher (PRV).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
LANGER DENNIS
(Last) (First) (Middle)
C/O QUOIN PHARMACEUTICALS LTD.,
42127 PLEASANT FOREST COURT
(Street)
ASHBURN VA 20148
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
ADSs(1) 10/14/2025 P(2) 15,152 A $8.49 15,153 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series H Warrants (Right to Buy) $9.075 10/14/2025 P(2) 15,152 10/14/2025(3) (4) ADS(1) 15,152 (2) 15,152 D
Series I Warrants (Right to Buy) $10.3125 10/14/2025 P(2) 15,152 10/14/2025(3) (5) ADS(1) 15,152 (2) 15,152 D
Series J Warrants (Right to Buy) $12.375 10/14/2025 P(2) 15,152 10/14/2025(3) (6) ADS(1) 15,152 (2) 15,152 D
Series K Warrants (Right to Buy) $12.375 10/14/2025 P(2) 15,152 10/14/2025(3) (7) ADS(1) 15,152 (2) 15,152 D
Explanation of Responses:
1. Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
2. Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."
3. The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
4. The Series H Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the Company's public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome.
5. The Series I Warrants will expire as follows: (i) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome, and (ii) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome.
6. The Series J Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome.
7. The Series K Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the Company's sale of a Priority Review Voucher (PRV).
/s/ Dennis Langer 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR